Home › Osteosarcoma › Maryland › Baltimore
Osteosarcoma clinical trials in Baltimore, MD
4 studies for Osteosarcoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RecruitingPhase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RecruitingPhase 2
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Osteosarcoma trials in other cities
- Memphis, TN10 studies
- Atlanta, GA10 studies
- St. Louis, MO10 studies
- Boston, MA9 studies
- Mountain View, CA8 studies
- Chicago, IL7 studies
- Los Angeles, CA7 studies
- Birmingham, AL7 studies
- Houston, TX7 studies
- Tampa, FL6 studies
- Washington, DC6 studies
- Philadelphia, PA6 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.